{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}],"title":"No renal involvement"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Renal Involvement, improved"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Normal Renal Function after Kidney Transplant"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"24 months post-initiation of treatment following the 3 phase comprehensive treatment approach including induction with BD, followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.","groups":[{"description":"Participants with newly diagnosed AL amyloidosis","id":"OG000","title":"Amyloidosis"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participants died at the previous 12 month follow up point","reportingStatus":"POSTED","timeFrame":"24 months","title":"Organ Response - Renal Involvement at 24 Months","type":"SECONDARY","unitOfMeasure":"Participants"}